S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Forecast, Price & News

$4.28
+0.17 (+4.14%)
(As of 09/22/2023 ET)
Compare
Today's Range
$4.00
$4.49
50-Day Range
$3.74
$5.40
52-Week Range
$0.85
$6.20
Volume
130,747 shs
Average Volume
101,415 shs
Market Capitalization
$42.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
285.5% Upside
$16.50 Price Target
Short Interest
Healthy
1.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.34) to ($1.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

194th out of 962 stocks

Electromedical Equipment Industry

5th out of 22 stocks


SLNO stock logo

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Price History

SLNO Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
SLNO Soleno Therapeutics, Inc.
7 Top Short-Squeeze Candidates to Watch in February
Oppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
SLNO.OQ - | Stock Price & Latest News | Reuters
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLNO
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+285.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-24,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.27 per share

Miscellaneous

Free Float
7,624,000
Market Cap
$42.76 million
Optionable
Not Optionable
Beta
0.15
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 53)
    Pres, CEO, COO & Director
    Comp: $835.2k
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 59)
    Chief Financial Officer
    Comp: $539k
  • Ms. Patricia C. Hirano (Age 57)
    VP of Regulatory Affairs
    Comp: $423.8k
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., MBA, Sr. VP of Drug Devel.
  • Ms. Kristen Yen M.S. (Age 54)
    VP of Clinical Operations













SLNO Stock - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 1-year target prices for Soleno Therapeutics' shares. Their SLNO share price forecasts range from $14.00 to $19.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 285.5% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2023?

Soleno Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, SLNO shares have increased by 116.2% and is now trading at $4.28.
View the best growth stocks for 2023 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.11.

When did Soleno Therapeutics' stock split?

Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (22.10%), Worth Venture Partners LLC (0.91%), Renaissance Technologies LLC (0.66%) and Geode Capital Management LLC (0.55%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Perceptive Advisors Llc and William G Harris.
View institutional ownership trends
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $4.28.

How much money does Soleno Therapeutics make?

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $42.76 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -